Idelalisib monotherapy results in durable responses in patients with relapsed or refractory Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Coutre, S. [1 ]
Leonard, J. [2 ]
Flowers, C. [3 ]
Davies, A. [4 ]
Jurczak, W. [5 ]
Byrd, J. [6 ]
Spurgeon, S. [7 ]
Peterman, S. [8 ]
Holes, L. [8 ]
Cho, Y. [8 ]
Sorenson, B. [8 ]
Godfrey, W. [8 ]
Gopal, A. [9 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Weill Cornell Med Ctr, New York, NY USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] Southampton Gen Hosp, Southampton, Hants, England
[5] Malopolskie Ctr Med SC, Krakow, Poland
[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[7] Oregon Hlth & Sci Univ, Portland, OR USA
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Univ Washington, Sch Med, Seattle, WA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
246
引用
下载
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [41] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [42] Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment na ve (TN) Waldenstrom macroglobulinemia (WM).
    Paludo, Jonas
    Abeykoon, Jithma P.
    Gertz, Morie A.
    Kumar, Shaji
    King, Rebecca L.
    Kyle, Robert A.
    Buadi, Francis
    Hayman, Suzanne R.
    Habermann, Thomas Matthew
    Dingli, David
    Witzig, Thomas E.
    Dispenzieri, Angela
    Lacy, Martha
    Thompson, Carrie A.
    Go, Ronald S.
    Gonsalves, Wilson I.
    Lust, John Anthony
    Rajkumar, S. Vincent
    Ansell, Stephen Maxted
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenstrom's macroglobulinemia
    Gavriatopoulou, Maria
    Kastritis, Efstathios
    Kyrtsonis, Marie-Christine
    Vassilakopoulos, Theodoros P.
    Roussou, Maria
    Fotiou, Despoina
    Migkou, Magdalini
    Mpakiri, Maria
    Tasidou, Anna
    Terpos, Evangelos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1506 - 1508
  • [44] Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia
    Paludo, Jonas
    Abeykoon, Jithma P.
    Kumar, Shaji
    Shreders, Amanda
    Ailawadhi, Sikander
    Gertz, Morie A.
    Kourelis, Taxiarchis
    King, Rebecca L.
    Reeder, Craig B.
    Leung, Nelson
    Kyle, Robert A.
    Buadi, Francis K.
    Habermann, Thomas M.
    Dingli, David
    Witzig, Thomas E.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Warsame, Rahma
    Lust, John A.
    Rajkumar, S. Vincent
    Ansell, Stephen M.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (01) : 98 - 105
  • [45] Symptomatic Waldenstrom's macroglobulinemia (WM) in young patients: Disease characteristics and outcome
    Kastritis, Efstathios
    Eleftherakis-Papaiakovou, Evangelos
    Migkou, Magdalini
    Gika, Dimitra
    Terpos, Evangelos
    Zervas, Konstantinos
    Kyrtsonis, Marie Christine
    Anagnostopoulos, Nicolaos
    Delimpassi, Sossana
    Symeonidis, Argiris
    Dimopoulos, Meletios Athanasios
    BLOOD, 2007, 110 (11) : 256B - 256B
  • [46] Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom Macroglobulinemia: Preliminary results
    Ghobrial, Irene M.
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Nelson, Marybeth
    Leduc, Renee
    Leleu, Xavier
    Warren, Diane
    Soumerai, Jacob
    Birner, Ann
    Schlossman, Robert
    Munshi, Nikhil
    Richardson, Paul
    Treon, Steven P.
    Anderson, Kenneth C.
    BLOOD, 2007, 110 (11) : 195B - 195B
  • [47] A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia
    Treon, Steven Peter
    Tripsas, Christina K.
    Yang, Guang
    Cao, Yang
    Xu, Lian
    Hunter, Zachary
    Cropper, Steven J.
    Mostyn, Patrick
    Meid, Kirsten
    Warren, Diane
    Patterson, Christopher
    Varma, Gaurav
    Laubach, Jacob P.
    Paba-Prada, Claudia E.
    Kunsman, Janet
    Ghobrial, Irene M.
    Kanan, Sandra
    Advani, Ranjana H.
    Palomba, Maria Lia
    BLOOD, 2013, 122 (21)
  • [48] Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248
    Treon, Steven P.
    Hunter, Zachary R.
    Matous, Jeffrey
    Joyce, Robin M.
    Mannion, Brian
    Advani, Ranjana
    Cook, David
    Songer, Joseph
    Hill, John
    Kaden, Bruce R.
    Sharon, David
    Steiss, Ronald
    Leleu, Xavier
    Branagan, Andrew R.
    Badros, Ashraf
    CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3320 - 3325
  • [49] Phase II study of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Interim results of WMCTG 03-248
    Treon, S
    Hunter, Z
    Matous, J
    Badros, A
    Joyce, R
    Mannion, B
    Advani, R
    Cook, D
    Songer, J
    Hill, J
    Kaden, B
    Steiss, R
    Branagan, A
    Patteron, C
    Mitsiades, C
    Anderson, K
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 66
  • [50] Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM)
    A Anagnostopoulos
    S Giralt
    Bone Marrow Transplantation, 2002, 29 : 943 - 947
12345